MorphoSys Expands Target Discovery Capability in Oridis Biomed Collaboration

18-Sep-2001

MorphoSys AG (Neuer Markt: MOR), the German biotechnology company, announced today that a court in San Diego has granted its motion to dismiss a second attempt by Cambridge Antibody Technology Ltd. (CAT), together with The Medical Research Council, The Scripps Research Institute and Stratagene to bring a suit alleging infringement of their "Winter II" US patent (No. 6,248,516). In late June, the Court dismissed CAT’s earlier-filed suit against MorphoSys on the same patent. Prior to CAT’s second filing, MorphoSys filed a suit in a District Court in Washington, DC seeking a declaration of non-infringement and invalidity of the Winter II patent.

"This collaboration is of significant strategic importance to MorphoSys", commented Dr. Thomas von Rueden, Chief Scientific Officer, MorphoSys AG. "Oridis Biomed’s access to one of the largest collections of human tissues, coupled with their expertise in protein expression analysis is complementary to our high throughput antibody generation capability. We anticipate the collaboration will help lead us to a number of new starting points for our own proprietary HuCAL®-based product-pipeline."

"By combining with MorphoSys’ technology, we now intend to apply the full potential of our tissue banks towards developing new medicines for diseases for which the current treatments are insufficient or for which there are no treatments at all," explains Professor Dr. Kurt Zatloukal, Chairman of the Board at Oridis Biomed.

The tissue collection resides at the Institute of Pathology, University of Graz, Austria. With 1.4 million paraffin-embedded and 18,000 frozen human tissue samples, the collection is one of the largest in the world. Under an agreement with the Institute, Oridis Biomed has exclusive rights to exploit the collection for commercial purposes. The collection contains a large number of annotated healthy and diseased tissues, and is expected to be exploited by Oridis Biomed to map and quantify the occurrence of potential therapeutic targets.

https://www.chemeurope.com/en/news/4724/morphosys-expands-target-discovery-capability-in-oridis-biomed-collaboration.html